1. Anti-CD37 antibodies for chronic lymphocytic leukemia. (May 2014) Authors: Robak, Tadeusz; Robak, Pawel Journal: Expert opinion on biological therapy Issue: Volume 14:Number 5(2014:May) Page Start: 651 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. BCR Signaling in Chronic Lymphocytic Leukemia and Related Inhibitors Currently in Clinical Studies. (1st August 2013) Authors: Robak, Tadeusz; Robak, Pawel Journal: International reviews of immunology Issue: Volume 32:Number 4(2013:Aug.) Page Start: 358 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Bone lesions in hairy cell leukemia: Diagnosis and treatment. (19th August 2020) Authors: Robak, Pawel; Jesionek‐Kupnicka, Dorota; Kupnicki, Piotr; Polliack, Aaron; Robak, Tadeusz Journal: European journal of haematology Issue: Volume 105:Number 6(2020) Page Start: 682 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Drug resistance in multiple myeloma. (November 2018) Authors: Robak, Pawel; Drozdz, Izabela; Szemraj, Janusz; Robak, Tadeusz Journal: Cancer treatment reviews Issue: Volume 70(2018) Page Start: 199 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Emerging antibody-drug conjugates for treating lymphoid malignancies. (3rd July 2017) Authors: Wolska-Washer, Anna; Robak, Pawel; Smolewski, Piotr; Robak, Tadeusz Journal: Expert opinion on emerging drugs Issue: Volume 22:Number 3(2017:Sep.) Page Start: 259 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Emerging immunological drugs for chronic lymphocytic leukemia. (September 2015) Authors: Robak, Pawel; Smolewski, Piotr; Robak, Tadeusz Journal: Expert opinion on emerging drugs Issue: Volume 20:Number 3(2015:Sep.) Page Start: 423 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Immunotherapy combinations for chronic lymphocytic leukemia: advantages and disadvantages. (2nd January 2023) Authors: Robak, Pawel; Robak, Tadeusz Journal: Expert opinion on biological therapy Issue: Volume 23:Number 1(2023) Page Start: 21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Mantle cell lymphoma: therapeutic options in transplant-ineligible patients. Issue 11 (19th September 2019) Authors: Robak, Tadeusz; Smolewski, Piotr; Robak, Pawel; Dreyling, Martin Journal: Leukemia & lymphoma Issue: Volume 60:Issue 11(2019) Page Start: 2622 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Issue 2 (February 2022) Authors: Schjesvold, Fredrik H; Dimopoulos, Meletios-Athanasios; Delimpasi, Sosana; Robak, Pawel; Coriu, Daniel; Legiec, Wojciech; Pour, Luděk; Špička, Ivan; Masszi, Tamas; Doronin, Vadim; Minarik, Jiri; Salogub, Galina; Alekseeva, Yulia; Lazzaro, Antonio; Maisnar, Vladimir; Mikala, Gábor; Rosiñol, Laura;... Journal: Lancet Issue: Volume 9:Issue 2(2022) Page Start: e98 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia. (2nd November 2017) Authors: Robak, Pawel; Robak, Tadeusz Journal: Expert opinion on investigational drugs Issue: Volume 26:Number 11(2017) Page Start: 1249 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗